To: Richard Kahn
From: Lesley Groff
Sent: Thur 1/17/2019 9:04:31 PM
Subject: Re:

Thx

Sent from my iPhone

On Jan 17, 2019, at 3:50 PM, Richard Kahn <u><richardkahn</u> <u>I 2@smail.com></u> wrote:

i will mention to jee when we speak next thanks

Richard Kahn
HBRK Associates Inc.
575 Lexington Avenue 4th Floor
New York, NY 10022

On Jan 17, 2019, at 12:19 PM, Lesley Groff wrote:



requested I forward you the below 'catch up' email.

- Image content: screenshot of an email body fully redacted (large black rectangle) — no readable email text.
- Visible filename under image: <1506365439123blob.jpg>
- Surrounding context: user note — "requested I forward you the below 'catch up' email."
- Actionable: cannot extract the email content due to redaction; please provide an unredacted image or the original text to capture details.

Forwarded Message
From: <d
To: <u>jeevacation@gmail.com</u> <ieevacation@gmail.com>:

Sent: Wednesday, January 16, 2019, 11:22:06 PM EST
Subject: Catching Up

Dear Jeffrey

I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see ifI might use the foundation's Lexington office conference room from time to time for my work and what I could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email?

Since working for your foundation, I continued to publish as a journalist writing mostly about genetic vectors (Newsweek, Techonomy etc). I then set up an LLC that provides business age-driven or development degenerative for diseases. labs that Most have of reversed the therapies are genetic vectors, and have to show remarkable results at the mouse level and beyond. Regenerative medicine is a rapidly evolving field, and one that forces the medical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls.

So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the ncuroglobin gene) under formal licence review with a publicly traded pharma group here in the US. And I am collaborating with a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver disease in rats using the master transcription gene in hepatocytes. The concept of the latter gene vector is really intriguing in that a master transcription gene completely restored liver function by rebalancing genetic expression and thus proteostasis.

While I don't really need an office at this point, I do need access to a conference room from time to time and it would be hugely helpful if I could access the foundation's. If there was some work that I could do for the foundation in exchange, I would be delighted to do that.

Key entities: Message with closing "all the best," and the mention of catching up. Contact information (redacted). Two instances of the filename "<1506365439123blob.jpg>."